



PATENT
Attorney Docket 036870-5073-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Holroyd et al.**

Application No. **10/772,437**

Filed: **February 6, 2004**

Allowed: **November 16, 2006**

Examiner: **Prema Maria Mertz**

Art Unit: **1646**

For: **Methods for treating ICACC protein associated diseases (Amended)**

COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

In response to the Examiner's Statement of Reasons for Allowance in the Notice of Allowability dated November 16, 2006, the following comments are submitted under 37 C.F.R. 1.104(e).

While Applicants believe that the claims are allowable and patentably distinguishable over the prior art, Applicants do not acquiesce that patentability resides in each feature, exactly as expressed in the claims, nor that each and every feature is required for patentability. Applicants submit that patentability is based on the claimed invention as a whole, and not solely on one or more particular features recited in the allowed claims.

Dated: **February 16, 2007**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP

Robert Smyth

Robert Smyth
Registration No. 50,801